Trial Profile

Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Estradiol (Primary) ; Estradiol (Primary) ; Goserelin; Goserelin; Leuprorelin; Leuprorelin; Triptorelin; Triptorelin
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms PATCH

Most Recent Events

13 May 2024 Planned End Date changed from 1 Sep 2024 to 1 Feb 2026.
01 Jan 2024 Results from NCT00303784 and NCT00268476 assessing androgen suppression, quality of life and bone health indices and cardiovascular events , published in the Clinical Oncology
17 Apr 2023 Status changed from completed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com